Search
Cupric Chloride
go.drugbank.com/drugs/DB09131ApprovedCupric chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).
Mixtures: Tracel Injektionslösung in einer Fertigspritze, Trace Elements Solution InjSynonyms: copper(II) chlorideRiboflavin
go.drugbank.com/drugs/DB00140ApprovedInvestigationalNutraceuticalVet approvedIt occurs in the free form only in the retina of the eye, in whey, and in urine; its principal forms in tissues and cells are as flavin mononucleotide and flavin-adenine dinucleotide. … Nutritional factor found in milk, eggs, malted barley, liver, kidney, heart, and leafy vegetables. The richest natural source is yeast.
Mixtures: Multi II IV Vi Tab, Vc IICapsaicin
go.drugbank.com/drugs/DB06774ApprovedInvestigationalCapsaicin is most often used as a topical analgesic and exists in many formulations of cream, liquid, and patch preparations of various strengths; however, it may also be found in some dietary supplements … Capsaicin is a naturally-occurring botanical irritant in chili peppers, synthetically derived for pharmaceutical formulations.
Mixtures: Tianhe Gutong Tiegao (in Polyisobutylene Carrier), Transderm-IQSynonyms: (E)-8-Methyl-N-vanillyl-6-nonenamide, trans-8-Methyl-N-vanillyl-6-nonenamideZolbetuximab
go.drugbank.com/drugs/DB15118ApprovedInvestigational[L51923] It is specifically targeted against CLDN18.2, a membrane protein normally found in gastric mucosal cells which is overexpressed in 30-50% of gastric and gastroesophageal junction (GEJ) adenocarcinomas … [A264723] Zolbetuximab was approved by the FDA in October 2024 for use in patients with HER2 negative, CLDN18.2-positive gastric and GEJ adenocarcinomas.[L51943,L51923]
Lorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalinclude lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. … It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to
Tislelizumab
go.drugbank.com/drugs/DB14922ApprovedInvestigational[L49439] Tislelizumab was also approved by the FDA on March 14, 2024.[L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349] … This approval was based on positive results demonstrated in the RATIONALE 302 study, where an 8.6-month median overall survival rate was observed for tislelizumab treatment compared to 6.3-month for chemotherapy
Sodium phosphate, monobasic
go.drugbank.com/drugs/DB09449ApprovedInvestigationalSodium phosphate is a saline laxative that is thought to work by increasing fluid in the small intestine. It usually results in a bowel movement after 30 minutes to 6 hours.
Mixtures: NUTRIFLEX PLUS IN 1000ML TWIN FLEX, NUTRIFLEX PLUS IN 2000ML TWIN FLEXSunitinib
go.drugbank.com/drugs/DB01268ApprovedInvestigationalIn addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. … Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor.
Ensartinib
go.drugbank.com/drugs/DB14860ApprovedInvestigational[A265030] The drug is 10-fold more potent in the inhibition of the growth of ALK-positive lung cancer cell lines when compared to [crizotinib]. … [A273963, A273958] Ensartinib is a first-line treatment for anaplastic lymphoma kinase (ALK)-mutated non-small cell lung cancer (NSCLC).
Moxonidine
go.drugbank.com/drugs/DB09242ApprovedInvestigationalWithdrawnIt is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive. … Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension.